Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03179943
Recruitment Status : Active, not recruiting
First Posted : June 7, 2017
Last Update Posted : November 4, 2021
Stand Up To Cancer
Van Andel Research Institute
Information provided by (Responsible Party):
Fox Chase Cancer Center

Brief Summary:
This is a single arm Phase II study with a safety run-in to identify the recommended phase II dose of the combination therapy of atezolizumab and guadecitabine. Patients with recurrent/advanced urothelial carcinoma (stage IV) who had previously progressed on check-point inhibitor therapy with PD-1 or PD-L1 targeting agents are eligible for this study. After a dose that is safe and tolerable has been established, a dose expansion phase (Phase II) will begin. This study will enroll a total of 4 to 53 patients depending upon the number of patients treated in the safety run-in phase and the number of subjects replaced during the phase II portion.

Condition or disease Intervention/treatment Phase
Urothelial Carcinoma Drug: Atezolizumab Drug: Guadecitabine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer
Actual Study Start Date : November 27, 2017
Actual Primary Completion Date : July 12, 2020
Estimated Study Completion Date : July 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Atezolizumab + Guadecitabine Drug: Atezolizumab
Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.

Drug: Guadecitabine
Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles

Primary Outcome Measures :
  1. Maximum tolerated dose of Guadecitabine in combination of Atezolizumab in safety run-in phase [ Time Frame: 2-3 months ]
    Dose de-escalation study based on standard 3+3 design will be conducted to test two dose levels of guadecitabine: 45mg/m2 and 36mg/m2 to determine MTD

  2. Objective Response Rate (RECIST v 1.1) in Phase II [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: 2 years ]
  2. Progression Free Survival [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have histologically confirmed urothelial carcinoma that is advanced or metastatic.
  2. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1 and ≥ 1 site safe for biopsy.
  3. Patient must agree to provide fresh biopsy specimens and peripheral blood samples at the time of screening and during the study.
  4. Patients must have received or be ineligible for platinum based chemotherapy and must have received at least one line of therapy with a PD-L1 or PD-1 targeting agent.
  5. Age > 18 years.
  6. ECOG performance status ≤ 2
  7. Life expectancy ≥ 12 weeks
  8. Patients must have normal organ and marrow function as defined below

    • Leukocytes > 3,000/mcL
    • Absolute neutrophil count > 1,500/mcL
    • Platelets > 100,000/mcL
    • Hemoglobin > 9 g/dl (blood transfusion is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is maintained at ≥9.0 g/dL for 7 days or longer)
    • Total bilirubin ≤ 2.5 x institutional upper limit of normal (ULN).
    • AST/ALT (SGOT/SGPT) < 2.5 times institutional normal limits unless liver metastases are present in which case AST and ALT must be ≤ 5 x IULN.
    • Creatinine within normal institutional limits OR
    • Creatinine clearance > 30 Ml/min (Cockcroft-Gault formula or measured with 24h urine)
    • INR or PTT/PT ≤ 1.5 ULN unless patient is on stable therapeutic dose of warfarin
  9. Ability to understand and willingness to sign a written informed consent and HIPAA consent document
  10. Women of child bearing potential and men must agree to remain abstinent or use adequate contraception (failure rate <1%) for the duration of study and for 90 days after the completion of the therapy.

Exclusion Criteria:

  1. Patients who have had anti-cancer therapy within 2 weeks prior to entering the study.
  2. Patients receiving any other investigational agents
  3. Patients with active or untreated CNS disease. Patients previously treated for CNS disease must be asymptomatic and must not be using steroids for at least 4 weeks prior to starting the study treatment.
  4. Patients with active auto-immune disease requiring immunosuppressive medication.
  5. Patients treated with systemic immunostimulatory agents (such as interferons, IL 12) within 6 weeks of the start of the treatment or 5 half-lives of the drug, whichever is shorter.
  6. Treatment with systemic corticosteroids within 2 weeks prior to the start of the treatment. Patients that require inhaled or low-dose corticosteroids for COPD or asthma, mineralocorticoids are allowed.
  7. Patients with active malignancies in addition to urothelial carcinoma.
  8. Patients with prior treatment with hypomethylating agents.
  9. History of leptomeningeal disease
  10. Prior allogeneic stem cell or solid organ transplant.
  11. Uncontrolled effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
  12. Uncontrolled symptomatic hypercalcemia (>1.5mmol/L ionized calcium or calcium > 12mg/dl or corrected serum calcium > ULN)
  13. Mean QT interval corrected for heart rate (QTc) ≥ 470ms calculated from 3 ECGs using Frediricia's correction.
  14. Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1 except for endocrine AEs managed with replacement therapy. Any other AEs unresolved toxicities grade 2 or more from previous anti-cancer therapy, except alopecia, peripheral neuropathy or non-clinically significant lab abnormalities.
  15. Receipt of therapeutic oral or IV antibiotics within 2 weeks prior to the start of the study treatment.
  16. Active or prior documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)
  17. History of severe allergic, anaphylactic or hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
  18. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterations), drug-induced pneumonitis or idiopathic pneumonitis or evidence of interstitial lung disease or active non-infectious pneumonitis.
  19. Active tuberculosis
  20. Known hypersensitivity to Chinese hamster ovary cell products or any of the study drugs.
  21. Administration of a live, attenuated vaccine within 4 weeks of the start of treatment or anticipation that such a live, attenuated vaccine will be required during the study.
  22. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  23. Known HIV-positive patients on combination antiretroviral therapy are ineligible.
  24. Known history of HBV or HCV infection.
  25. Pregnant or breast feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03179943

Layout table for location information
United States, California
USC Norris Hospital and Clinics
Los Angeles, California, United States, 90033
United States, Maryland
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States, 21287
United States, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States, 19111
Sponsors and Collaborators
Fox Chase Cancer Center
Stand Up To Cancer
Van Andel Research Institute
Layout table for additonal information
Responsible Party: Fox Chase Cancer Center Identifier: NCT03179943    
Other Study ID Numbers: GU-114
SU2C-AACR-CT08-17 ( Other Grant/Funding Number: Stand up to Cancer )
First Posted: June 7, 2017    Key Record Dates
Last Update Posted: November 4, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Fox Chase Cancer Center:
bladder cancer
Ureteral Cancer
Urothelial cancer
Urethral cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents